In this issue:
Integrating local and systemic therapies:
Sunitinib alone or after nephrectomy in mRCC
Guidelines for cytoreductive nephrectomy in patients with synchronous metastatic clear-cell renal cell carcinoma
Outcomes for partial nephrectomy vs radical nephrectomy in mRCC
Effect of switching systemic treatment after SRS for oligoprogressive, mRCC
SRT in the strategy of treatment of mRCC
New ideas:
TRC105 (anti-endoglin antibody) with axitinib in mRCC
hERV signatures predict immunotherapy response in ccRCC
Evolving data:
Avelumab plus axitinib as first-line therapy in advanced ccRCC
ccRCC demonstrates suppressed glucose oxidation in vivo
Cabozantinib vs sunitinib as initial therapy for mRCC of intermediate or poor risk
Prevalence of cancer-related germline mutations in advanced RCC
Please login below to download this issue (PDF)